Adenocarcinoma — Trials

Adenocarcinoma — Trials · CancerIndex

Clinical trials

Registered studies

9,703 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 2,753
Recruiting: 1,520
Ph III recruiting: 168
Growth YoY: +6.8%
Industry share: 23%
Top sponsor: National Cancer Institute (NCI)
Termination share: 36.5%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,319)

clinicaltrialsPublishedShowing 301–350 of 1,275 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02953457	Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation	completed	Phase 2	40	Roswell Park Cancer InstituteOTHER	1	Nov 19, 2024	clinicaltrials
NCT03015740	Sitravatinib and Nivolumab in Treating Patients With Advanced or Metastatic Kidney Cancer	completed	Phase 1 / Phase 2	42	M.D. Anderson Cancer CenterOTHER	1	Nov 19, 2024